Filana Therapeutics (FLNA) Enterprise Value (2010 - 2026)
Filana Therapeutics (FLNA) posted quarterly Enterprise Value of -$82.7 million for Q2 2026, up 26.43% year-over-year from -$65.4 million in Q2 2025, and up 4.5% quarter-over-quarter from -$86.6 million in Q1 2026.
Filana Therapeutics (FLNA) Enterprise Value (2010 - 2026) Analysis & Trends
Filana Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$82.7 million for Q2 2026.
- In Q2 2026, Enterprise Value rose 26.43% year-over-year to -$82.7 million; the TTM figure through Jun 2026 stood at -$82.7 million (up 26.43% YoY), while the FY2025 annual figure was -$95.5 million, up 25.72% from the prior year.
- Enterprise Value for Q2 2026 stood at -$82.7 million, up from -$86.6 million in the prior quarter.
- The five-year high for Enterprise Value was -$82.7 million in Q2 2026, with the low at -$209.7 million in Q1 2022.
- The 5-year median for Enterprise Value is -$135.5 million (2023), against an average of -$147.3 million.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value plunged 32.76% in 2024, then jumped 45.79% in 2025.
- Filana Therapeutics' Enterprise Value stood at -$201.0 million in 2022, then surged by 39.74% to -$121.1 million in 2023, then fell by 6.14% to -$128.6 million in 2024, then advanced by 25.72% to -$95.5 million in 2025, then grew by 13.42% to -$82.7 million in 2026.
- Business Quant data shows FLNA's Enterprise Value at -$82.7 million in Q2 2026, -$86.6 million in Q1 2026, and -$95.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 2.12 Bn |
| 10 | Filana Therapeutics | 46.22 Mn | 46.22 Mn | - | -82.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -82.68 Mn |
| Mar 31, 2026 | -86.57 Mn |
| Dec 31, 2025 | -95.50 Mn |
| Sep 30, 2025 | -106.08 Mn |
| Jun 30, 2025 | -112.38 Mn |
| Mar 31, 2025 | -117.33 Mn |
| Dec 31, 2024 | -128.57 Mn |
| Sep 30, 2024 | -188.98 Mn |
| Jun 30, 2024 | -207.29 Mn |
| Mar 31, 2024 | -124.17 Mn |
| Dec 31, 2023 | -121.14 Mn |
| Sep 30, 2023 | -142.35 Mn |
| Jun 30, 2023 | -168.44 Mn |
| Mar 31, 2023 | -187.47 Mn |
| Dec 31, 2022 | -201.02 Mn |
| Sep 30, 2022 | -174.66 Mn |
| Jun 30, 2022 | -197.23 Mn |
| Mar 31, 2022 | -209.69 Mn |
| Dec 31, 2021 | -233.44 Mn |
| Sep 30, 2021 | -241.52 Mn |